Huadong

Official Launch of Carbon-Neutrality Pilot Project in the China-EU (Taicang) Green and Digital Innovation Cooperation Zone

Retrieved on: 
Wednesday, August 9, 2023

BEIJING, Aug. 9, 2023 /PRNewswire/ -- On August 8th 2023, the Launch Meeting of Carbon-Neutrality Pilot Project in China-EU (Taicang) Green Digital and Innovation Cooperation Zone was held in Beijing, China.

Key Points: 
  • BEIJING, Aug. 9, 2023 /PRNewswire/ -- On August 8th 2023, the Launch Meeting of Carbon-Neutrality Pilot Project in China-EU (Taicang) Green Digital and Innovation Cooperation Zone was held in Beijing, China.
  • The core of China-EU (Taicang) Pilot Project is a "Digital Zero-Carbon Industrial Park", located in Taicang City, Jiangsu Province in the Yangtze River Delta region of China, adjacent to Shanghai.
  • 150,000, setting the goal of carbon neutral by 2028 with a whole-area traceable carbon footprint based on digital system.
  • Currently, the Secretariat of China Green Sustainable Development Association (CGSDA) is soliciting pilot projects and partners for the year 2024, which is open for global application.

ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

Retrieved on: 
Monday, October 19, 2020

We look forward to working closely with Huadong Medicine to develop and commercialize mirvetuximab in Greater China as we advance the mirvetuximab program and prepare for the first potential commercial launch in the United States in 2022.

Key Points: 
  • We look forward to working closely with Huadong Medicine to develop and commercialize mirvetuximab in Greater China as we advance the mirvetuximab program and prepare for the first potential commercial launch in the United States in 2022.
  • ImmunoGen is also eligible to receive low double digit to high teen royalties as a percentage of mirvetuximab commercial sales by Huadong Medicine in Greater China.
  • Huadong Medicine will also have the opportunity to participate in global clinical studies of mirvetuximab conducted by ImmunoGen.
  • ImmunoGen will continue to be responsible for the development and commercialization of mirvetuximab in the United States and other geographies.

MediBeacon Enters into $30 Million Investment and Exclusive Commercialization Partnership in Greater China with Huadong Medicine

Retrieved on: 
Wednesday, July 31, 2019

The agreement will provide exclusive rights to MediBeacon's portfolio of assets in Greater China.

Key Points: 
  • The agreement will provide exclusive rights to MediBeacon's portfolio of assets in Greater China.
  • Huadong Medicine will fund all commercial and regulatory activities in Greater China and select Asian countries.
  • "We are extremely excited to partner with Huadong Medicine in Greater China," says Steve Hanley, CEO and Co-Founder of MediBeacon.
  • Learn more about Huadong Medicine at www.eastchinapharm.com
    2"Prevalence of chronic kidney disease in China: a cross-sectional survey", Zhang L. et al, Lancet.

MediBeacon Enters into $30 Million Investment and Exclusive Commercialization Partnership in Greater China with Huadong Medicine

Retrieved on: 
Wednesday, July 31, 2019

The agreement will provide exclusive rights to MediBeacon's portfolio of assets in Greater China.

Key Points: 
  • The agreement will provide exclusive rights to MediBeacon's portfolio of assets in Greater China.
  • Huadong Medicine will fund all commercial and regulatory activities in Greater China and select Asian countries.
  • "We are extremely excited to partner with Huadong Medicine in Greater China," says Steve Hanley, CEO and Co-Founder of MediBeacon.
  • Learn more about Huadong Medicine at www.eastchinapharm.com
    2"Prevalence of chronic kidney disease in China: a cross-sectional survey", Zhang L. et al, Lancet.